Skip to content
Peptide research

P21

Also known as P021 ยท Neurotrophic Peptide
Category
Brain & Cognition
Administration routes
Injectable
Regulatory status
Not FDA-approved

A synthetic CNTF-derived peptide marketed for cognitive enhancement and neuroprotection. The case rests entirely on animal studies of memory rescue and reduced tau and amyloid buildup; touted uses in macular degeneration and rare neurodevelopmental disorders remain speculative. There is no human safety data, and boosting neurogenesis carries a theoretical risk of uncontrolled cell growth. Not an approved drug; supply is unregulated research-grade material.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

P21 (also called P021) is a synthetic peptide mimetic designed to protect and regenerate brain cells. It was derived from the active region of CNTF (ciliary neurotrophic factor), a natural brain growth factor, by researchers at the New York State Institute for Basic Research, and contains a four-amino-acid CNTF core plus an added adamantane-based residue. The key innovation is that P21 can be taken orally and crosses the blood-brain barrier -- something the parent molecule CNTF cannot do. It works through a dual mechanism: boosting BDNF (the brain's primary growth and repair signal) while simultaneously reducing the abnormal tau protein buildup seen in Alzheimer's disease.

How it works in the body

A synthetic fragment derived from the active region of CNTF (ciliary neurotrophic factor). It partially inhibits signaling by the cytokine LIF, or leukemia inhibitory factor, reducing its suppressive effect on neurogenesis. This promotes the birth of new neurons in the hippocampus, which is critical for learning and memory formation.

Research overview

P21 has been studied exclusively in animal models over 14+ years, with roughly 15 publications led by Dr. Khalid Iqbal's lab. In Alzheimer's model mice, chronic oral P21 rescues memory deficits, reduces both amyloid plaques and tau tangles, prevents nerve cell death, and restores the brain's ability to form new connections. It has also shown benefits in Down syndrome mouse models and age-related cognitive decline in rats. Importantly, P21 works both as a treatment (after brain pathology develops) and as prevention (before it starts). Safety testing shows it is tolerated at up to 550x the therapeutic dose. Phanes Biotech is currently pursuing FDA approval studies, but no human clinical trials have been conducted yet. All evidence comes from a single research group, so independent replication is needed.

Who researches P21?

Commonly researched by

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

  • People researching rescues cognitive deficits and enhances learning and memory

    One of the primary studied benefits of P21.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High ยท Medium ยท Low ยท Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High ยท Moderate ยท Low ยท Theoretical
Interactions
= direction with this peptide: Protective / Synergistic ยท Caution ยท Neutral

Risk summary(5)

Rated by level of concern

  • No established human safety profile

    High

    No registered clinical trials identified; PMID 25046994

  • Potential for uncontrolled neurogenesis or cellular proliferation

    Theoretical

    PMID 19767127; PMID 25046994

  • Potential antibody formation

    Theoretical

    PMID 20600002; PMID 26401692

  • Contraindicated populations (theoretical)

    Theoretical

    PMID 32854771; PMID 19767127

  • Research chemical quality and purity concerns

    High

    No approved product or registered clinical trial identified

Interaction summary(8)

Rated by direction with this peptide

  • Recombinant CNTF, LIF, and other gp130/IL-6-family cytokine therapies

    CautionTheoretical

    P021 works by competitively inhibiting LIF signaling at the shared gp130 receptor complex, so co-administration with a gp130-family agonist would be directly antagonistic and could blunt or unpredictably alter both agents. Mechanism-based only; never studied.

    PMID 19767127 (LIF competitive inhibition); no interaction study exists

  • Anti-LIF oncology agents (e.g. anti-LIF monoclonal antibodies in development)

    SynergisticTheoretical

    These agents block the same ligand P021 antagonizes, so effects on LIF-gp130-STAT3 signaling would be expected to overlap - mechanistically additive, never studied in combination, and additive LIF blockade has no established safety margin. Purely inferential.

    Mechanism-based (shared LIF target); PMID 19767127 supports only P021's LIF antagonism, not the combination

  • Chronic systemic glucocorticoids (prednisone, dexamethasone)

    CautionTheoretical

    Sustained corticosteroid exposure suppresses hippocampal neurogenesis and BDNF expression, the exact axis P021 acts through, so chronic steroid use would be expected to oppose its principal mechanism.

    Mechanism-based (BDNF/neurogenesis axis; P021 mechanism per PMID 25046994)

  • Lithium and other GSK3-beta inhibitors

    CautionTheoretical

    P021's downstream effect on tau is mediated by BDNF-driven reduction in GSK3-beta activity, the same kinase lithium inhibits. The plausible consequence is over-suppression of a kinase with broad physiological roles, not a demonstrated additive benefit.

    Mechanism-based (BDNF -> GSK3-beta axis per PMID 25046994); no combination study exists

  • SSRIs and other antidepressants that raise BDNF

    SynergisticTheoretical

    SSRIs increase hippocampal BDNF and neurogenesis through a convergent pathway, so effects on that endpoint would likely be additive; no interaction study exists and no adverse signal has been reported.

    Mechanism-based convergence on BDNF/neurogenesis (P021 mechanism per PMID 25046994)

  • JAK inhibitors (tofacitinib, ruxolitinib, baricitinib)

    CautionTheoretical

    LIF signals through JAK/STAT3 downstream of gp130, so a JAK inhibitor and a LIF antagonist act on the same cascade at two points, with unstudied consequences for immune and hematopoietic function.

    Mechanism-based (gp130-JAK-STAT3 cascade; PMID 19767127 for P021 LIF antagonism)

  • Cholinesterase inhibitors (donepezil, rivastigmine) and memantine

    NeutralTheoretical

    These act on cholinergic and NMDA neurotransmission with no known overlap with LIF-gp130 or BDNF-GSK3-beta signaling, so no pharmacological interaction is predicted - though no co-administration study has been done.

    Mechanism-based (non-overlapping targets)

  • Chronic heavy alcohol use

    CautionTheoretical

    Alcohol robustly suppresses adult hippocampal neurogenesis in animal models, which would be expected to counteract the mechanism P021 depends on for its cognitive effects. The alcohol-neurogenesis effect is animal data and the interaction with P021 has never been studied in any species.

    Mechanism-based (neurogenesis suppression); no P021-specific study

Known risks(5)

  • No established human safety profile

    High (Unknown)

    P021 has never been tested in humans. All safety data comes from rodent studies. While animal data is encouraging (no adverse effects in up to 18 months of treatment, safe at 550x therapeutic dose in acute toxicology), the translation of animal safety to humans is never guaranteed. Unknown pharmacokinetics, metabolism, and potential toxicities in humans represent the primary risk.

  • Potential for uncontrolled neurogenesis or cellular proliferation

    Theoretical / Unknown

    P021 promotes neurogenesis and cellular proliferation via BDNF upregulation. Individuals with active cancer, a history of cancer, or predisposition to neoplastic conditions should exercise extreme caution, as stimulating cellular growth pathways could theoretically promote tumor growth. No tumors have been observed in animal studies, but this risk has not been evaluated in humans.

  • Potential antibody formation

    Low / Theoretical

    As a peptide-based compound, P021 could theoretically trigger antibody formation with repeated administration. A review of peptide drugs noted this as a possible adverse event, though no immune reaction to P021 has been observed in any preclinical study to date.

  • Contraindicated populations (theoretical)

    Moderate / Theoretical

    Based on the mechanism of action, the following populations should avoid P021: pregnant or breastfeeding individuals (neurogenesis effects on fetal/infant brain are unpredictable outside controlled prenatal models), individuals with epilepsy or seizure disorders (altered neuronal excitability), those with autoimmune conditions (immune pathway modulation via LIF/JAK-STAT), and individuals under 25 whose brains are still developing naturally.

  • Research chemical quality and purity concerns

    Moderate

    Unregulated P021 products sold online lack pharmaceutical-grade quality controls. Purity, sterility, endotoxin levels, and actual peptide content may vary among unregulated products sold online. Contamination or degradation products could pose additional unknown risks.

Drug interactions(6)

  • Other BDNF-enhancing compounds (Cerebrolysin, 7,8-DHF, NSI-189)

    P021 increases BDNF expression via LIF inhibition. Combining with other compounds that upregulate BDNF could produce excessive neurotrophic signaling. P021 was originally derived from CNTF, which is a component of Cerebrolysin โ€” combining P021 with Cerebrolysin may provide redundant CNTF-pathway activation. Use one or the other, not both.

  • Other neurogenic compounds (Dihexa, NSI-189, Semax)

    Combined neurogenic stimulation from multiple compounds acting through distinct pathways (P021 via LIF/BDNF, Dihexa via HGF/c-Met) could produce unpredictable effects on brain plasticity. While no overlapping direct targets suggest pharmacological conflict, combined neurogenic stimulation should be approached with caution and is entirely unstudied.

  • JAK inhibitors (tofacitinib, baricitinib, ruxolitinib)

    P021 acts by inhibiting the LIF/JAK-STAT3 signaling pathway. Co-administration with JAK inhibitors could produce additive or synergistic inhibition of JAK-STAT signaling, potentially leading to excessive immunosuppression or disruption of normal cytokine signaling.

  • GSK-3beta inhibitors (lithium, tideglusib)

    P021 indirectly inhibits GSK-3beta via the BDNF/PI3K/Akt pathway. Combining with direct GSK-3beta inhibitors like lithium could produce excessive GSK-3beta suppression, potentially disrupting Wnt signaling and glycogen metabolism. Monitor lithium levels closely if used concomitantly.

  • Immunomodulators and immunosuppressants

    P021 modulates the LIF/JAK-STAT3 and CNTF signaling pathways, which play roles in immune regulation. Interactions with immunomodulatory drugs are unstudied and could alter immune function in unpredictable ways.

  • Anti-seizure / anti-epileptic medications

    P021 promotes neurogenesis and increases synaptic excitability (upregulates NMDA and AMPA receptor subunits). This could theoretically lower the seizure threshold in susceptible individuals, potentially counteracting anti-seizure medications. Individuals with epilepsy or seizure disorders should avoid P021.

Research & benefits

Evidence base

Evidence Level
Preclinical Only
Total Studies
15
Human Studies
0

All evidence for P021 comes from in vitro and in vivo animal studies. No human clinical trials (Phase 1, 2, or 3) have been published or registered on ClinicalTrials.gov as of March 2026. Preclinical work spans several animal models (3xTg-AD mice, aged Fisher rats, Ts65Dn Down syndrome mice, Cdkl5 KO mice), treatment paradigms (therapeutic, preventive, developmental), and endpoints (cognition, tau/Abeta pathology, neurogenesis, synaptic markers, MRI microstructure), but findings vary by model: the CDKL5 mouse study did not reproduce the BDNF or neuroanatomical benefits reported in other animal models. Long-term administration (up to 18 months in mice) has shown no adverse effects including no weight loss, tumors, or pain. However, the absence of any human data means efficacy and safety in humans remain entirely unestablished.

Researched for(7)

Rated by confidence in the evidence

  • Rescues cognitive deficits and enhances learning and memory

    Low

    Extensive rodent studies show learning and memory gains; no human trials exist yet.

    PMID 20600002; PMID 24702821; PMID 25046994; PMID 28655344; PMID 28387677

  • Reduces abnormal tau hyperphosphorylation and neurofibrillary pathology

    Low

    Multiple rodent studies show reduced tau pathology via a defined mechanism; no human data yet.

    PMID 25046994; PMID 26401692; PMID 28387677

  • Reduces amyloid-beta plaque pathology

    Low

    Animal studies show mixed results, with amyloid reduction seen only in one lab's model.

    PMID 25046994; PMID 28387677; PMID 32854771

  • Promotes hippocampal neurogenesis and synaptic plasticity

    Low

    Well-defined mechanism with consistent animal data; no human neurogenesis imaging yet exists.

    PMID 19767127; PMID 20600002; PMID 28655344

  • Prevents age-related macular degeneration (AMD) pathology

    Speculative

    Based on a single unreplicated animal study of AMD-like retinal changes.

    PMID 31803044

  • Rescues developmental delay and cognitive deficits in Down syndrome model

    Speculative

    Single mouse study found developmental and memory rescue; unreplicated, no human data.

    PMID 28368015

  • Studied in a CDKL5 deficiency disorder model, with limited in vivo benefit

    Speculative

    In Cdkl5 KO mice, BDNF and brain structure did not improve; behavioral benefit was limited.

    PMID 39592934 (Mottolese et al. 2024, J Neurodevelop Disord)

Benefits(7)

  • Rescues cognitive deficits and enhances learning and memory

    Li et al. 2010 (PMID 20600002) โ€” P021 enhanced learning and both short-term and spatial reference memories in normal C57Bl6 mice. Kazim et al. 2014 (PMID 25046994) โ€” chronic oral P021 rescued cognitive deficits in 3xTg-AD mice at both moderate and severe disease stages.

  • Reduces abnormal tau hyperphosphorylation and neurofibrillary pathology

    Kazim et al. 2014 (PMID 25046994) โ€” P021 significantly reduced phosphorylated tau in 3xTg-AD mice. Baazaoui & Iqbal 2017 (PMID 28387677) โ€” early P021 treatment prevented tau pathology for up to 18 months. Khatoon et al. 2015 (PMID 26401692) โ€” P021 reduced elevated CSF tau in aged rats.

  • Reduces amyloid-beta plaque pathology

    Kazim et al. 2014 (PMID 25046994) โ€” P021 reduced Abeta pathology in 3xTg-AD mice. Baazaoui & Iqbal 2017 (PMID 28387677) โ€” preventive P021 treatment reduced Abeta accumulation when started months before pathology onset.

  • Promotes hippocampal neurogenesis and synaptic plasticity

    Li et al. 2010 (PMID 20600002) โ€” P021 induced neurogenesis and maturation of new neurons in the dentate gyrus. Bolognin et al. 2014 (PMID 24702821) โ€” P021 rescued age-dependent neurogenesis decline in 22-24 month old rats. Baazaoui & Iqbal 2017 (PMID 28655344) โ€” P021 prevented dendritic and synaptic deficits in 3xTg-AD mice.

  • Prevents age-related macular degeneration (AMD) pathology

    Liu et al. 2019 (PMID 31803044) โ€” chronic P021 treatment ameliorated photoreceptor degeneration, RPE atrophy, Bruch's membrane thickening, and retinal tau/Abeta pathology in aged rats and 3xTg-AD mice.

  • Rescues developmental delay and cognitive deficits in Down syndrome model

    Kazim et al. 2017 (PMID 28368015) โ€” prenatal-to-postnatal P021 treatment rescued developmental delay in pups and Alzheimer's-like memory deficits in adult Ts65Dn mice (Down syndrome model). Increased BDNF levels two-fold.

  • Studied in a CDKL5 deficiency disorder model, with limited in vivo benefit

    Mottolese et al. 2024 (PMID 39592934) โ€” P021 improved proliferation, survival and maturation in CDKL5-deficient cultured cells. In mice, it did not increase BDNF or improve neuroanatomical defects; behavioral benefit was limited.

Key studies(5)

  1. Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice

    Preclinical (in vivo, normal mice)Multiple cohorts of C57Bl6 miceAcute and subchronic (subcutaneous pellets, 35 days)

    Bin Li, Lukas Wanka, Julie Blanchard, Fei Liu, Muhammad Omar Chohan, Khalid Iqbal, Inge Grundke-Iqbal

    FEBS Letters

    2010

    First publication on P021. The peptidergic compound Ac-DGGLAG-NH2 (P021), when administered peripherally via subcutaneous extended-release pellets (25 nM/day for 35 days), enhanced learning and both short-term and spatial reference memories in normal adult C57Bl6 mice. P021 induced neurogenesis and maturation of newly born neurons in the granular cell layer and subgranular zone of the dentate gyrus.

  2. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease

    Preclinical (in vivo, 3xTg-AD transgenic mice)Multiple cohorts of 3xTg-AD and wild-type mice6-12 months oral treatment (60 nmol/g feed)

    Syed Faraz Kazim, Julie Blanchard, Chun-Ling Dai, Yunn-Chyn Tung, Frank M LaFerla, Inge Grundke-Iqbal, Khalid Iqbal

    Neurobiology of Disease

    2014

    Chronic oral P021 treatment at both moderate (9-10 month old) and severe (15-18 month old) disease stages in 3xTg-AD mice significantly rescued cognitive deficits, reduced tau hyperphosphorylation, decreased amyloid-beta pathology, and restored neurogenesis and synaptic plasticity. Demonstrated disease-modifying potential of P021 in an Alzheimer's model. Daily intake was approximately 162 nmol P021 per mouse per day.

  3. Prevention of Amyloid-beta and Tau Pathologies, Associated Neurodegeneration, and Cognitive Deficit by Early Treatment with a Neurotrophic Compound

    Preclinical (in vivo, 3xTg-AD transgenic mice)Multiple cohorts of 3xTg-AD female miceUp to 18 months oral treatment (starting at 3 months of age)

    Baazaoui N, Iqbal K

    Journal of Alzheimer's Disease

    2017

    P021 treatment initiated during the synaptic compensation period (3 months old, several months before any overt pathology) and continued for up to 18 months prevented amyloid-beta and tau pathologies, associated neurodegeneration, and cognitive deficits in 3xTg-AD mice. Results followed at 9, 15, and 18 months post-treatment onset. Demonstrates secondary prevention potential.

  4. Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome

    Preclinical (in vivo, Ts65Dn Down syndrome mice)Multiple cohorts of Ts65Dn and 2N control micePrenatal (E8) through postnatal day 24, with follow-up to adulthood

    Kazim SF, Blanchard J, Bianchi R, Iqbal K

    Scientific Reports

    2017

    Prenatal-to-early-postnatal P021 treatment (via maternal diet) rescued developmental delay in pups and Alzheimer's-like hippocampus-dependent memory impairments in adult life in the Ts65Dn Down syndrome mouse model. P021 decreased GSK-3beta activity and increased BDNF by two-fold and phospho-CREB levels in both young and adult mice.

  5. Diffusion MRI measures detect brain microstructure changes due to early treatment with neurotrophic peptide mimetic P021 in the 3xTg-AD mouse model of Alzheimer's disease

    Preclinical (in vivo, 3xTg-AD mice, diffusion MRI)Multiple cohorts of 3xTg-AD and wild-type miceChronic oral treatment

    Falangola MF, Voltin J, Cole M, Nietert PJ, Liu F, Iqbal K, Jensen JH

    Magnetic Resonance Imaging

    2026

    Diffusion MRI confirmed that chronic P021 treatment ameliorates both white matter and gray matter microstructural deficits in 3xTg-AD mice, possibly via BDNF-mediated myelin restoration and neuroprotection. Long-term P021 administration showed no undesirable side effects. Demonstrates non-invasive imaging biomarker potential for tracking P021 treatment response.

Regulation & availability

Why researchers look at it

In Alzheimer's model mice, chronic oral dosing rescued memory, reduced amyloid plaques and tau tangles, prevented nerve cell death, and stimulated new brain cell growth โ€” effects no approved drug achieves simultaneously โ€” with safety at up to 550x the therapeutic dose. All evidence comes from a single research group over 14 years with zero human trials; Phanes Biotech is pursuing IND-enabling studies.

FDA status
Not FDA Approved โ€” Preclinical Stage. P021 has not undergone any FDA-regulated human clinical trials. No Investigational New Drug (IND) application has been publicly announced, though Phanes Biotech has stated they are conducting IND-enabling studies including GMP manufacturing (three batches of multi-gram amounts completed), off-target effects screening, and acute toxicology studies. The compound was found safe at up to 550-fold the therapeutic dose in acute toxicology studies, with plans for multi-kilogram manufacture and IND filing to be followed by human clinical trials. No timeline for IND submission or Phase 1 trial initiation has been publicly disclosed. P021 is not listed in any FDA database (Drugs@FDA, Orange Book, or approved product listings).
WADA status
P021 is not individually named. Under its described unapproved pharmacological status, S0 prohibits it at all times unless another section applies. Individual naming is unnecessary.
Prescribability
Not Prescribable โ€” Preclinical Investigational Compound. P021 has not been approved by any regulatory agency for human use and is not available by prescription. It is currently in preclinical/IND-enabling development by Phanes Biotech.
Availability
P021 is NOT approved for human use and is not available by prescription anywhere in the world. It is an investigational compound in preclinical development by Phanes Biotech Inc. (Pennsylvania, USA). P021 has >95% stability in artificial gastric juice over 30 minutes, approximately 100% stability in intestinal fluid over 120 minutes, plasma stability >3 hours, and is blood-brain barrier permeable, which enables oral and intranasal routes of administration.

International status

  • EU

    Not approved

  • US

    Not FDA-approved

  • Worldwide

    No regulatory approval in any jurisdiction

Regulatory timeline(10)

  1. 2010
    First publication describing P021 (Ac-DGGLAG-NH2) โ€” Li et al. in FEBS Letters demonstrate cognitive enhancement and neurogenesis in normal mice
  2. 2014
    Kazim et al. publish disease-modifying effects of chronic oral P021 in 3xTg-AD Alzheimer's mice (Neurobiology of Disease). Bolognin et al. demonstrate rescue of cognitive aging in aged Fisher rats (Neurobiology of Aging)
  3. 2015
    Khatoon et al. show P021 is BBB-permeable and reduces CSF tau in aged rats (Journal of Alzheimer's Disease)
  4. 2016
    Kazim & Iqbal publish comprehensive review of neurotrophic factor small-molecule mimetics for AD including P021 (Molecular Neurodegeneration)
  5. 2017
    Three major publications: prevention of Abeta/tau pathologies with early P021 treatment (Baazaoui & Iqbal, J Alzheimers Dis); prevention of dendritic/synaptic deficits (Baazaoui & Iqbal, Alzheimers Res Ther); rescue of Down syndrome developmental delay (Kazim et al., Sci Rep)
  6. 2019
    Liu et al. demonstrate P021 prevents age-related macular degeneration pathology in aged rats and 3xTg-AD mice (Frontiers in Aging Neuroscience)
  7. 2020-2021
    Wei et al. publish two studies on prenatal-to-postnatal P021 treatment preventing AD-like behavior and pathology (Alzheimers Res Ther 2020; J Alzheimers Dis 2021)
  8. 2022
    Baazaoui & Iqbal publish review: 'Alzheimer's Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound' (Biomolecules)
  9. 2024
    Mottolese et al. demonstrate P021 efficacy in CDKL5 deficiency disorder model (J Neurodevelop Disord). Iqbal publishes career retrospective including P021 development (Cytoskeleton). Phanes Biotech announces completion of multi-gram GMP manufacturing, off-target screening, and acute toxicology (safe at 550x dose)
  10. 2026
    Falangola et al. publish the diffusion MRI study of P021 treatment effects on brain microstructure in Alzheimer's-model mice (Magnetic Resonance Imaging). Phanes Biotech continues IND-enabling studies with plans for multi-kilogram manufacture

Sources & FAQs

Research sources(18)

Frequently asked questions(5)

What is P021 and how does it differ from full-length CNTF?

P021 is a synthetic peptide mimetic made from the DGGL tetrapeptide region of CNTF with an added adamantane-based terminal residue. Unlike full-length CNTF, which cannot cross the blood-brain barrier and caused dose-limiting side effects in clinical trials (anorexia, weight loss, hyperalgesia), P021 is BBB-permeable, orally bioavailable, highly stable in gastric and intestinal fluid, and has shown no adverse effects in animal studies lasting up to 18 months. The adamantylated glycine at the C-terminal is what gives P021 these druggable properties.

Has P021 been tested in humans?

No. As of March 2026, P021 has been studied exclusively in animal models (mice and rats). No Phase 1, 2, or 3 human clinical trials have been published or registered. Phanes Biotech is conducting IND-enabling studies with the goal of eventually starting human clinical trials, but no specific timeline has been announced. All efficacy and safety data are from preclinical studies only.

How is P021 administered in research studies?

In the majority of preclinical studies, P021 was administered orally, incorporated into the animal diet. The original 2010 study used subcutaneous extended-release pellets.

What diseases or conditions is P021 being investigated for?

P021 has been studied in animal models of Alzheimer's disease (primary focus), cognitive aging, Down syndrome, CDKL5 deficiency disorder (a severe epileptic encephalopathy), and age-related macular degeneration. All of these conditions share underlying features of neurodegeneration, impaired neurogenesis, or synaptic plasticity deficits that P021's neurotrophic mechanism addresses.

Is P021 safe to use?

There is no established human safety profile for P021. In animal studies, chronic oral treatment for up to 18 months in mice produced no observable adverse effects including no weight loss, no tumors, and no signs of pain. Acute toxicology testing by Phanes Biotech showed safety at up to 550-fold the therapeutic dose. No immune reaction or antibody formation against P021 has been detected. However, the absence of any human data means safety in humans is entirely unknown. Anyone considering self-administration is doing so with an unapproved research chemical at their own risk.